FindMyKOL

Azeez Farooki, MD

Basic profile

Memorial Sloan Kettering Cancer Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Azeez Farooki is an Endocrinology/Metabolic physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 103 publications with 4,359 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
103publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,359citations

Citations across these publications.

28h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Ascendis Pharma Endocrinology Inc
    Program year202519 payments
    $14,105
  • KYOWA KIRIN, INC.
    Program year20258 payments
    $4,214
  • BETA BIONICS, INC.
    Program year202516 payments
    $646
All 37 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    52.6%
    Insulin Analog13.3%
    Humalog Kwikpen U-10030%Lantus Solostar30%Novolog Flexpen19%Tresiba Flextouch U-1009%Toujeo Solostar7%Basaglar Kwikpen U-1006%
    Part D<11 patients
    Biguanide (metformin)11.1%
    Metformin Hcl67%Metformin Hcl Er34%
    Part D≥39 patients

    + 7 more classes in this area

  • Cardiovascular

    22.1%
    Statin12.3%
    Atorvastatin Calcium58%Rosuvastatin Calcium42%
    Part D≥33 patients
    Cholesterol absorption inhibitor2.1%
    Ezetimibe100%
    Part D<11 patients

    + 6 more classes in this area

  • Hormonal (systemic)

    19.5%
    l-Thyroxine11.9%
    Levothyroxine Sodium79%Synthroid21%
    Part D≥45 patients
    Calcium-sensing Receptor Agonist2.2%
    Cinacalcet Hcl100%
    Part D≥13 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”